Search

EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia

EHA in close collaboration with the Estonian Society of Haematology, the Lithuanian Society of Hematology and the Latvian Hematology Society are organizing the first EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia.

Read more

Registration & accommodation

Register here

Individual registrationIn-person registration fee includes:

Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks and lunches on April 25 and 26 
Access to the poster sessions and…

Read more

Abstract Submission & Travel Grant Application

Late Poster Submission is now closed.

Read more

Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and Reliable Supply Chain for Plasma-Derived Products

The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.

Read more

Joint EHA and national society membership

Enjoy the best of both worlds—and save money—by combining an EHA membership with membership of your national hematology society. This special type of membership package is the result of our constructive collaborations with a range of national hematology societies.

Read more

EHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma

Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev 

This meeting will be held in English and offer a simultaneous translation to Russian.

Read more

EU funding approved for TOLERATE

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more